Investment in Cellnovo's facilities in order to develop its innovative connected all-in-one diabetes management system focused primarily on type 1 diabetes patients
The aim of the project is to scale up production of Cellnovo's novel micro-pump for type 1 diabetes patients and support related capital expenditure for products it plans to bring to the market in the future.
All project activities are expected to be carried out in existing facilities without changing the already authorised scope and would therefore not require an environmental impact assessment (EIA) under Directive 2014/52/EU amending the EIA Directive 2011/92/EU.
The promoter has been assessed by the EIB as being a private company not subject to EU rules on public procurement or concessions.
News & Stories
General enquiries and comments
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.
Zero tolerance against fraud and corruption